On 10/7/25, OncoCyte Corp (NASDAQ: OCX) stock enjoyed a major increase of 12.2%, closing at $3.68. This advance was accompanied by normal trading volume. The stock has risen 13.9% during the last week and has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
OncoCyte is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment